{"id":"nrp104","safety":{"commonSideEffects":[{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Increased heart rate"},{"rate":null,"effect":"Elevated blood pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NRP104 is a long-acting prodrug formulation of d-amphetamine designed to provide extended therapeutic coverage. The drug is metabolized in the body to release d-amphetamine, which acts as a sympathomimetic amine that increases the release and blocks the reuptake of norepinephrine and dopamine in the central nervous system, thereby improving attention and reducing hyperactivity and impulsivity in ADHD patients.","oneSentence":"NRP104 is a prodrug that delivers d-amphetamine to the central nervous system for the treatment of attention-deficit/hyperactivity disorder (ADHD).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:35.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults"}]},"trialDetails":[{"nctId":"NCT07314333","phase":"PHASE1","title":"A Trial to Assess How Centanafadine Interacts With Stimulants in the Body","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-02-05","conditions":"ADHD","enrollment":42},{"nctId":"NCT06788587","phase":"PHASE2","title":"Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2025-07-18","conditions":"Methamphetamine Abuse, Methamphetamine-dependence, Addiction","enrollment":80},{"nctId":"NCT05854667","phase":"PHASE2","title":"Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2023-12-05","conditions":"Methamphetamine Abuse, Methamphetamine-dependence, Addiction, Substance","enrollment":440},{"nctId":"NCT04599504","phase":"PHASE2, PHASE3","title":"Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2022-01-02","conditions":"Loss-of-control Eating, Obesity/Overweight","enrollment":60},{"nctId":"NCT05416125","phase":"EARLY_PHASE1","title":"Vyvanse in Children Aged 6 to 12 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2023-12-20","conditions":"Obesity, Childhood","enrollment":44},{"nctId":"NCT03926052","phase":"PHASE3","title":"Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-08-07","conditions":"Binge-Eating Disorder, Obesity","enrollment":61},{"nctId":"NCT06847399","phase":"PHASE2","title":"Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-09-17","conditions":"Obesity and Overweight, Binge Eating Disorder","enrollment":105},{"nctId":"NCT01071044","phase":"PHASE4","title":"Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome","status":"COMPLETED","sponsor":"Rochester Center for Behavioral Medicine","startDate":"2009-11","conditions":"Chronic Fatigue Syndrome, Cognitive Impairments","enrollment":26},{"nctId":"NCT07098585","phase":"PHASE1","title":"To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions.","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-05-26","conditions":"Attention Deficit/Hyperactivity Disorder (ADHD)","enrollment":48},{"nctId":"NCT04132557","phase":"","title":"A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":430000},{"nctId":"NCT03497169","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2016-11-02","conditions":"Obesity, Morbid","enrollment":12},{"nctId":"NCT01342445","phase":"PHASE4","title":"Effects of LDX on Functioning of College Students With ADHD","status":"COMPLETED","sponsor":"University of Rhode Island","startDate":"2009-09","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":50},{"nctId":"NCT03420339","phase":"PHASE4","title":"Stimulant Effects on Disruptive Behavior","status":"RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2018-10-01","conditions":"Attention Deficit Hyperactivity Disorder, Problem Behavior","enrollment":10},{"nctId":"NCT05957055","phase":"PHASE2","title":"Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2024-02-05","conditions":"Attention Deficit Disorder with Hyperactivity, Diabetes Mellitus, Type 1","enrollment":150},{"nctId":"NCT04737512","phase":"EARLY_PHASE1","title":"Mindfulness-Based ADHD Treatment for Children: a Feasibility Study","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-02-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":68},{"nctId":"NCT03924193","phase":"PHASE3","title":"Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-03-25","conditions":"Binge-Eating Disorder, Obesity","enrollment":141},{"nctId":"NCT05551689","phase":"NA","title":"FOCUS ADHD Mobile Health App for Adult ADHD Patients","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2021-05-21","conditions":"ADHD","enrollment":73},{"nctId":"NCT03337646","phase":"PHASE4","title":"Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism","status":"COMPLETED","sponsor":"JPM van Stralen Medicine Professional","startDate":"2018-09-26","conditions":"Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder","enrollment":48},{"nctId":"NCT03187353","phase":"PHASE4","title":"IMProving Executive Function Study","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-09-22","conditions":"Cognitive Impairment, RRSO","enrollment":69},{"nctId":"NCT02136147","phase":"","title":"ADHD Medication and Predictors of Treatment Outcome","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-06","conditions":"Attention Deficit Disorder With Hyperactivity (ADHD)","enrollment":632},{"nctId":"NCT04946461","phase":"","title":"The Day-time Response Variation of (Lis)Dexamphetamine","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2021-07-01","conditions":"Adhd","enrollment":16},{"nctId":"NCT02259517","phase":"NA","title":"An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2014-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":38},{"nctId":"NCT01074294","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-03-16","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":740},{"nctId":"NCT04577417","phase":"","title":"Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2020-09-13","conditions":"Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity","enrollment":70},{"nctId":"NCT01615887","phase":"PHASE2","title":"Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2009-11","conditions":"Multiple Sclerosis","enrollment":63},{"nctId":"NCT03333668","phase":"NA","title":"Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents","status":"UNKNOWN","sponsor":"King's College London","startDate":"2018-10-01","conditions":"ADHD","enrollment":20},{"nctId":"NCT01415440","phase":"NA","title":"Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-08","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":117},{"nctId":"NCT00500071","phase":"PHASE4","title":"Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD","status":"COMPLETED","sponsor":"Shire","startDate":"2007-06-28","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":318},{"nctId":"NCT01913912","phase":"PHASE3","title":"Event Rate and Effects of Stimulants in ADHD","status":"WITHDRAWN","sponsor":"University Ghent","startDate":"2014-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT04866043","phase":"","title":"Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2019-06-01","conditions":"Binge-eating Disorder","enrollment":150},{"nctId":"NCT02635035","phase":"PHASE2","title":"Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2015-11","conditions":"Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder","enrollment":38},{"nctId":"NCT04152629","phase":"PHASE4","title":"Real World Evidence of the Efficacy and Safety of FOQUEST","status":"COMPLETED","sponsor":"Purdue Pharma, Canada","startDate":"2019-09-19","conditions":"Attention Deficit-Hyperactivity Disorder","enrollment":257},{"nctId":"NCT04727476","phase":"","title":"The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders","status":"UNKNOWN","sponsor":"Aarhus University Hospital","startDate":"2021-01-19","conditions":"Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Hyperkinetic Disorder","enrollment":413},{"nctId":"NCT01718509","phase":"PHASE3","title":"SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-11-26","conditions":"Binge Eating Disorder","enrollment":390},{"nctId":"NCT03446885","phase":"PHASE4","title":"Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD","status":"COMPLETED","sponsor":"Gregory Fabiano","startDate":"2018-04-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":22},{"nctId":"NCT01738698","phase":"PHASE3","title":"Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2012-11-01","conditions":"Schizophrenia","enrollment":4},{"nctId":"NCT00877487","phase":"PHASE4","title":"Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2009-04-30","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":123},{"nctId":"NCT01760889","phase":"PHASE3","title":"SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2013-02-01","conditions":"Schizophrenia","enrollment":1},{"nctId":"NCT01760993","phase":"PHASE3","title":"Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2013-02-01","conditions":"Schizophrenia","enrollment":2},{"nctId":"NCT00500149","phase":"PHASE3","title":"A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2007-06-13","conditions":"ADHD","enrollment":129},{"nctId":"NCT01235338","phase":"PHASE1","title":"Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2010-10-28","conditions":"Healthy","enrollment":80},{"nctId":"NCT01436175","phase":"PHASE3","title":"SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study","status":"TERMINATED","sponsor":"Shire","startDate":"2012-02-27","conditions":"Major Depressive Disorder","enrollment":1570},{"nctId":"NCT00735371","phase":"PHASE3","title":"Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2008-10-08","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":314},{"nctId":"NCT00763971","phase":"PHASE3","title":"Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2008-11-17","conditions":"ADHD","enrollment":336},{"nctId":"NCT00919867","phase":"PHASE1","title":"A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2009-06-24","conditions":"Healthy","enrollment":42},{"nctId":"NCT00746733","phase":"PHASE1","title":"Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC","status":"COMPLETED","sponsor":"Shire","startDate":"2008-09-08","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT01096680","phase":"PHASE2","title":"Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss","status":"COMPLETED","sponsor":"Shire","startDate":"2010-04-05","conditions":"Sleep Deprivation","enrollment":135},{"nctId":"NCT00764868","phase":"PHASE3","title":"Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study","status":"COMPLETED","sponsor":"Shire","startDate":"2008-11-13","conditions":"ADHD","enrollment":269},{"nctId":"NCT00905424","phase":"PHASE2","title":"Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant","status":"COMPLETED","sponsor":"Shire","startDate":"2009-07-30","conditions":"Major Depressive Disorder","enrollment":246},{"nctId":"NCT01010750","phase":"PHASE1","title":"Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2010-01-05","conditions":"Attention-Deficit Hyperactivity Disorder","enrollment":18},{"nctId":"NCT02009163","phase":"PHASE3","title":"Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2014-01-27","conditions":"Binge Eating Disorder","enrollment":418},{"nctId":"NCT01106430","phase":"PHASE3","title":"Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate","status":"COMPLETED","sponsor":"Shire","startDate":"2010-06-28","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":267},{"nctId":"NCT01328756","phase":"PHASE4","title":"Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2011-07-07","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":314},{"nctId":"NCT01552902","phase":"PHASE4","title":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-04-03","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":549},{"nctId":"NCT01291173","phase":"PHASE2","title":"Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-05-10","conditions":"Binge Eating Disorder","enrollment":271},{"nctId":"NCT01435759","phase":"PHASE2","title":"SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-05-31","conditions":"Major Depressive Disorder","enrollment":1197},{"nctId":"NCT01101022","phase":"PHASE4","title":"Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2010-05-19","conditions":"ADHD Specifically With Executive Function Impairment","enrollment":161},{"nctId":"NCT00922272","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms","status":"COMPLETED","sponsor":"Shire","startDate":"2009-09-14","conditions":"Schizophrenia and Predominant Negative Symptoms","enrollment":92},{"nctId":"NCT00697515","phase":"PHASE3","title":"Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2008-07-18","conditions":"ADHD","enrollment":142},{"nctId":"NCT01436162","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-19","conditions":"Major Depressive Disorder","enrollment":1105},{"nctId":"NCT01657019","phase":"PHASE3","title":"Open Label Extension in Adults With Binge Eating Disorder (BED)","status":"COMPLETED","sponsor":"Shire","startDate":"2012-08-21","conditions":"Binge Eating Disorder","enrollment":604},{"nctId":"NCT00776555","phase":"PHASE1","title":"Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution","status":"TERMINATED","sponsor":"Shire","startDate":"2008-11-21","conditions":"Healthy","enrollment":3},{"nctId":"NCT01436149","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-27","conditions":"Major Depressive Disorder","enrollment":1262},{"nctId":"NCT00784654","phase":"PHASE3","title":"Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2009-01-27","conditions":"ADHD","enrollment":276},{"nctId":"NCT03260205","phase":"PHASE3","title":"Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2017-09-06","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":199},{"nctId":"NCT01552915","phase":"PHASE4","title":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-04-17","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":464},{"nctId":"NCT01718483","phase":"PHASE3","title":"SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-11-26","conditions":"Binge Eating Disorder","enrollment":383},{"nctId":"NCT00985725","phase":"PHASE2","title":"SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2009-10-29","conditions":"Major Depressive Disorder","enrollment":143},{"nctId":"NCT01274221","phase":"PHASE3","title":"Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"WITHDRAWN","sponsor":"Shire","startDate":"2011-03-06","conditions":"ADHD","enrollment":""},{"nctId":"NCT01234298","phase":"PHASE3","title":"SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia","status":"WITHDRAWN","sponsor":"Shire","startDate":"2012-01-27","conditions":"Negative Symptoms of Schizophrenia","enrollment":""},{"nctId":"NCT01457339","phase":"PHASE1","title":"Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-21","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT01890785","phase":"PHASE1","title":"Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2013-07-15","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT02466386","phase":"PHASE3","title":"Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2015-08-21","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":113},{"nctId":"NCT03397446","phase":"PHASE2","title":"Lisdexamfetamine for Adults With Bulimia Nervosa","status":"TERMINATED","sponsor":"Aaron Keshen","startDate":"2018-06-21","conditions":"Bulimia Nervosa","enrollment":23},{"nctId":"NCT04181957","phase":"NA","title":"Effects of LDX on Cognitive Processes and Appetite","status":"TERMINATED","sponsor":"University of Birmingham","startDate":"2019-05-01","conditions":"Binge Eating, Eating Behavior","enrollment":22},{"nctId":"NCT02712996","phase":"PHASE4","title":"Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2017-02-06","conditions":"Traumatic Brain Injury, Attention Deficit Disorder","enrollment":20},{"nctId":"NCT02170298","phase":"PHASE4","title":"Lisdexamfetamine's Effect In ADHD in the Brain and Cognition","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2014-02","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":6},{"nctId":"NCT01490216","phase":"PHASE1","title":"Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2011-07","conditions":"Cocaine Dependence","enrollment":43},{"nctId":"NCT01486810","phase":"PHASE1, PHASE2","title":"Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-12","conditions":"Cocaine Dependence","enrollment":17},{"nctId":"NCT02668926","phase":"PHASE1","title":"Endocrine and Emotional Effects of Lisdexamfetamine and d-Amphetamine.","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-05","conditions":"Healthy","enrollment":24},{"nctId":"NCT00736255","phase":"NA","title":"Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-12","conditions":"Attention Deficit Hyperactivity Disorder, Nicotine Dependence","enrollment":32},{"nctId":"NCT01399827","phase":"PHASE2","title":"Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-02","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)","enrollment":2},{"nctId":"NCT01816074","phase":"PHASE4","title":"Sequencing Treatments for Mothers With ADHD and Their At - Risk Children","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2012-10","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":53},{"nctId":"NCT02675400","phase":"PHASE4","title":"Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2015-12","conditions":"Attention Deficit/Hyperactivity Disorder (ADHD)","enrollment":19},{"nctId":"NCT02210728","phase":"NA","title":"Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder","status":"UNKNOWN","sponsor":"Lily Hechtman","startDate":"2006-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":200},{"nctId":"NCT02142140","phase":"NA","title":"Follow up Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2012-12","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":326},{"nctId":"NCT03070509","phase":"PHASE4","title":"Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients","status":"UNKNOWN","sponsor":"North Dakota State University","startDate":"2017-05-12","conditions":"Lisdexamfetamine","enrollment":20},{"nctId":"NCT02788851","phase":"NA","title":"The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-04","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":70},{"nctId":"NCT02566824","phase":"PHASE4","title":"Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2010-10","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":216},{"nctId":"NCT01977625","phase":"PHASE4","title":"LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-12","conditions":"Menopause, Brain Activity, Cognition","enrollment":18},{"nctId":"NCT01924429","phase":"PHASE4","title":"Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation","status":"COMPLETED","sponsor":"Jeffrey Newcorn","startDate":"2013-03","conditions":"ADHD","enrollment":30},{"nctId":"NCT01070394","phase":"PHASE4","title":"Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2010-02","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":40},{"nctId":"NCT01714310","phase":"PHASE2","title":"Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2013-01","conditions":"Severe Mood Dysregulation","enrollment":34},{"nctId":"NCT00733356","phase":"PHASE4","title":"The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading","status":"COMPLETED","sponsor":"Kimberley Lakes","startDate":"2008-07","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":42},{"nctId":"NCT01986777","phase":"NA","title":"LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2013-07","conditions":"Cognitive Impairments, RRSO","enrollment":""},{"nctId":"NCT02034201","phase":"PHASE1","title":"Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2014-02","conditions":"Methamphetamine Dependence","enrollment":19},{"nctId":"NCT01863459","phase":"PHASE4","title":"Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity","status":"COMPLETED","sponsor":"Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada","startDate":"2013-04","conditions":"Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders","enrollment":42},{"nctId":"NCT02204410","phase":"PHASE4","title":"Omega-3 Supplementation to ADHD Medication in Children","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-07","conditions":"Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation","enrollment":21},{"nctId":"NCT01324024","phase":"PHASE4","title":"Attention & Memory Impairments in Menopausal Women","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-05","conditions":"Symptomatic Menopause, Cognitive Impairments","enrollment":35},{"nctId":"NCT01148979","phase":"PHASE4","title":"Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2010-09","conditions":"Major Depressive Disorder","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["lisdexamfetamine dimesylate"],"phase":"phase_3","status":"active","brandName":"NRP104","genericName":"NRP104","companyName":"New River Pharmaceuticals","companyId":"new-river-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NRP104 is a prodrug that delivers d-amphetamine to the central nervous system for the treatment of attention-deficit/hyperactivity disorder (ADHD). Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}